[Clinical research of xinganbao capsule on the treatment of chronic hepatitis B liver fibrosis].
OBJECTIVE
To explore the effects of Xinganbao Capsule (Cordyceps Sinensis) on the chronic hepatitis B liver fibrosis.


METHODS
Sixty patients with chronic hepatitis B were randomly assigned to the trail group (40 cases) and the control group (20 cases). The trail group was treated with Xinganbao Capsule, 8 capsules each time, three times a day. The control group was given Heluo Shugan Tablet, 5 pills each time, thrice daily. Six months consisted of one therapeutic course. The liver function, four indicators of serum fibrosis, liver histology, and other items were detected.


RESULTS
Xinganbao Capsule could reduce serum ALT and AST levels, serum HA, PC-III and LN levels (all P<0.05), showing statistical difference when compared with before treatment. The HA and LN levels decreased more significantly in the control group when compared with before treatment (P<0.05). Totally 21 patients (53% of the recruited cases) in the trial group completed the liver biopsy twice. After treated with Xinganbao Capsule, 81% patients (17/21) had decreased liver inflammation 1 grade or more, 52% patients (11/21) had decreased fibrosis staging one or more, and 33% (7/21) patients had no change in fibrosis.


CONCLUSIONS
Xinganbao Capsule could improve the liver function, reduce liver inflammation, and fight against hepatic fibrosis.
Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015.
Xian-Bo
XB
Wang
Yu-Yong
YY
Jiang
Cai-Yan
CY
Zhao
D000328:Adult; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D016896:Treatment Outcome
D004365:Drugs, Chinese Herbal